The ESDR regrets to inform its community that Detlef Zillikens, Professor and Chair of the Department of Dermatology at the University of Schleswig Holstein in Lubeck, Germany, passed away on 19 September 2022. He had been unwell since earlier this year. He was 64.
The 51st Annual ESDR Meeting abstract book is now available online. Download the abstract book here.
SKIN AS A WORK OF ART PEAUrigami® ESDR is pleased to welcome Corinne Dechelette, PharmD, PhD (skin...
🔹NEW 🔹 The best submissions, as judged by the scientific program committee, will be considered for...
We have published an obituary of Jean-Paul Ortonne submitted from his friends and colleagues...
Travel Awards for Dermatology and Skin Science Trainees from Egypt, Jordan, South Africa, Tunisia...
About The ESDR
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of over 1200.
By supporting investigative dermatology, the ESDR contributes towards improving the health of patients suffering from skin and venereal disease. Applications of recent scientific advances have produced diagnostic and therapeutic innovations in dermatological practice, particularly in genetics, skin cancer, allergic skin disease, infectious disease and autoimmune diseases.
join the esdr
The Journal of Investigative Dermatology (JID) is the official journal of the ESDR and SID. JID publishes papers describing original research on all aspects of cutaneous biology and skin disease. Topics include biochemistry, biophysics, cell regulation, carcinogenesis, skin structure, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, physiology, pharmacology, photobiology, percutaneous absorption, clinical research, epidemiology and other population-based research.
- Neoadjuvant systemic therapy for Merkel cell carcinoma: A Tertiary Referral Center Experience
- Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WT Merkel cell carcinoma (MCC)
- Repurposing disulfiram for the treatment of Merkel cell carcinoma
- Virally mediated mechanisms of HLA class I loss in Merkel cell carcinoma and implications for viral epitope presentation
- EDITORS’ PICKS